DE201165T1 - Arzneimittel zur behandlung von emesis, anxietas und "irritable bowel syndrome". - Google Patents
Arzneimittel zur behandlung von emesis, anxietas und "irritable bowel syndrome".Info
- Publication number
- DE201165T1 DE201165T1 DE198686301684T DE86301684T DE201165T1 DE 201165 T1 DE201165 T1 DE 201165T1 DE 198686301684 T DE198686301684 T DE 198686301684T DE 86301684 T DE86301684 T DE 86301684T DE 201165 T1 DE201165 T1 DE 201165T1
- Authority
- DE
- Germany
- Prior art keywords
- formula
- alkyl
- hydrogen
- group
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002551 irritable bowel syndrome Diseases 0.000 title claims 3
- 206010047700 Vomiting Diseases 0.000 title claims 2
- 239000003814 drug Substances 0.000 title claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- -1 hydroxy, amino Chemical group 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 125000005236 alkanoylamino group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (10)
1. Die Verwendung einer Verbindung der Formel(I) oder (II)
oder eines pharmazeutisch verträglichen Salzes derselben:
Ar-CO-Y-Z (I)
in welcher Ar eine Gruppe der Formel (a) ist:
(a)
in welcher
R. und R_ unabhängig voneinander ausgewählt sind aus
Wasserstoff, Halogen, C ,-Alkyl, C -Alkoxy, Hydroxy, Amino, gegebenenfalls substituiert durch eine oder zwei C 4-Alkylgruppen,.Thiolbzw.C 4-Alkylthio; X CH2,NR3,-0- oder -S- bedeutet, wobei R3 Wasserstoff, C ^-Alkyl, C3 Alkenyl, Phenyl oder Phenyl-C. .-alkyl ist:
Wasserstoff, Halogen, C ,-Alkyl, C -Alkoxy, Hydroxy, Amino, gegebenenfalls substituiert durch eine oder zwei C 4-Alkylgruppen,.Thiolbzw.C 4-Alkylthio; X CH2,NR3,-0- oder -S- bedeutet, wobei R3 Wasserstoff, C ^-Alkyl, C3 Alkenyl, Phenyl oder Phenyl-C. .-alkyl ist:
oder Ar eine Gruppe der Formel (b) ist:
(b)
in welcher R. bis R7 unabhängig voneinander Wasserstoff,
Halogen, C ,-Alkyl, C ,-Alkoxy, Hydroxy, Amino, gegebenenfalls
substituiert durch eine oder zwei C .-Alkyl, C ^-alkanoylamino- oder Pyrrolylgruppen-sind und eine
der Gruppen :R. his R7 kein Wasserstoff ist;
Y -O- oder -NH- bedeutet; und
Z eine Gruppe der Formel (c), (d) oder (e) ist:
(CH JnNR8
(C)
in welcher
&eegr; 2,3 oder 4 ist;
R„ Wasserstoff, C '-Alkyl, C -Alkenyl oder Phenyl C
.-alkyl, gegebenenfalls substituiert durch ein oder zwei Halogen(e), C1-4-AIkOXy oder C ,-Alkyl, bedeutet;
in welchen
&rgr; den Wert 1, 2 oder 3 hat; und
Rn die gleiche Definition hat wie R0;
y ö
mit der Maßgabe, daß, wenn Ar die Formel(b) hat und Y -NH- ist, Z eine Gruppe der Formel (d) oder (e) ist:
(II)
in welcher
R10 Wasserstoff, C, 1Q-Alkyl, C _,-Cycloalkyl, C3-6"
Alkenyl, Phenyl oder Phenyl-C ,-alkyl ist; und
eine der Gruppen, dargestellt durch R11, R1^ und. R13,
Wasserstoff, C.g-Alkyl, (!.,.-,-Cycloalkyl, C ,-Alkenyl
oder Phenyl-C .,-alkyl ist und jede der anderen Gruppen,
welche gleich oder verschieden sein können, Wasserstoff oder C fi-Alkyl ist; zur Herstellung eines Medikaments
* · ♦ ft ·
-A-
fiir die Behandlung von Erbrechen, Angstzuständen und/oder Darmreizsyndrom(IBS).
2. Verwendung nach Anspruch 1, wobei die Verbindung die Formel(I) hat, Ar die Formel
wie in Anspruch 1 definiert.
wie in Anspruch 1 definiert.
Formel(I) hat, Ar die Formel (a) hat, und X NR3 ist,
3. Verwendung nach Anspruch 1, wobei die Verbindung die Formel(I) hat, Ar die Formel (b)hat, wobei R Wasserstoff
und R1-/ Rfi und R_ unabhängig voneinander Halogen-vC fi-
#lkyl- oder C._fi-Alkoxygruppen sind.
4. Verwendung nach Anspruch 1, wobei die Verbindung die Formel(IA) hat:
co—Y—
Rl
(IA)
in welcher Z eine Gruppe der Formel(c) ist, wie in Anspruch 1 definiert,und R1»Ro und Y wie in Anspruch
1 definiert sind.
5. Verwendung nach Anspruch 1, wobei die Verbindung die
Formel(IB) hat:
CO-O—Z
(IB)
in welcher R Halo, C1 ,-Alkyl oder C ,-Alkoxy ist,
1 5 &iacgr;&ogr;- &iacgr;&ogr;
R Wasserstoff oder C1 ,-Alkoxy ist; R^ ' Halogen,C1 ,-Alkyl
oder C ,-Alkoxy ist und Z wie in Anspruch 4 definiert
ist.
6. Verwendung nach Anspruch 1, wobei die Verbindung die
Formel(IE) hat:
CO—Y—Z"
N-
(IE)
in welcher Z eine Gruppe der Formel(e)ist und R.,R^
und Y wie in Anspruch 1 definiert sind.
7. Verwendung nach Anspruch 4,5 oder 6, wobei Rg oder R»
Methyl oder Äthyl sind.
8. Verwendung nach Anspruch 1, wobei die Verbindung die
Formel(IIA) hat:
(HA)
in welcher R ein Wasserstoffatom oder eineMethyl-,
Äthyl-/Propyl-,Prop-2-y1-,Prop-2-enyl-oder Cyclopenty1-gruppe
ist; R ein Wasserstoffatom bedeutet; und ent-
1
weder R11 eineMethyl-,Äthyl7,Propyl-oder Pröp-2-ylgruppe
weder R11 eineMethyl-,Äthyl7,Propyl-oder Pröp-2-ylgruppe
1 1
ist und
ein Wasserstoffatom darstellt oder
ein
Wasserstoffatom ist und ist.
eine Methyl- oder Äthylgruppe
1 1
9. Verwendung nach Anspruch 8, wobei R1n Methyl und R «
und R13 jeweils Wasserstoff bedeuten.
10. Verwendung nach Anspruch 1, wobei die Verbindung der
Formel(I) oder (II) ausgewählt ist aus der Gruppe bestehend
aus:
3, S-Dichlor-zOcc- (S-methyl-S-azabicyclo(3. 2.1) octyljbenzoat,
Indol-/~3a:- (8-methy1-8-azabicyclo (3.2.1) octy 1/-3-carboxylat,
3 , 5-Dimethyl-/f3^-(8-methy 1-azabicyclo (3.2.1) octy\7-benzoat,
Indol-/B-(2-methy1-2-azabicyclo(2.2.2)octyl/-3-carboxylat,
1 , 2,3,9-Tetrahydro-9-methyl-3-/~(2-methyl-1H-imidazol-1-yl)
methy]L7-4H-carbazol-4-on ,·
oder ein pharmazeutisch verträgliches Salz einer dieser Verbindungen.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB858506642A GB8506642D0 (en) | 1985-03-14 | 1985-03-14 | Compounds |
| GB858509039A GB8509039D0 (en) | 1985-04-09 | 1985-04-09 | Treatment |
| GB858531614A GB8531614D0 (en) | 1985-12-23 | 1985-12-23 | Treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE201165T1 true DE201165T1 (de) | 1989-04-20 |
Family
ID=27262620
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3689974T Expired - Lifetime DE3689974T2 (de) | 1985-03-14 | 1986-03-10 | Arzneimittel zur Behandlung von Emesis. |
| DE199090107640T Pending DE385517T1 (de) | 1985-03-14 | 1986-03-10 | Arzneimittel zur behandlung von erbrechen. |
| DE198686301684T Pending DE201165T1 (de) | 1985-03-14 | 1986-03-10 | Arzneimittel zur behandlung von emesis, anxietas und "irritable bowel syndrome". |
| DE90107640T Expired - Lifetime DE3688296T2 (de) | 1985-03-14 | 1986-03-10 | Arzneimittel zur behandlung von erbrechen. |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3689974T Expired - Lifetime DE3689974T2 (de) | 1985-03-14 | 1986-03-10 | Arzneimittel zur Behandlung von Emesis. |
| DE199090107640T Pending DE385517T1 (de) | 1985-03-14 | 1986-03-10 | Arzneimittel zur behandlung von erbrechen. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE90107640T Expired - Lifetime DE3688296T2 (de) | 1985-03-14 | 1986-03-10 | Arzneimittel zur behandlung von erbrechen. |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US4721720A (de) |
| EP (3) | EP0405617A3 (de) |
| JP (3) | JPS61212521A (de) |
| CY (1) | CY1727A (de) |
| DE (4) | DE3689974T2 (de) |
| HK (1) | HK77593A (de) |
| SG (1) | SG61693G (de) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5122528A (en) * | 1983-12-22 | 1992-06-16 | Erbamont, Inc. | Analgesic use of benzobicyclic carboxamides |
| US4820715A (en) * | 1984-06-28 | 1989-04-11 | Bristol-Myers Company | Anti-emetic quinuclidinyl benzamides |
| DE3587151T2 (de) * | 1984-12-20 | 1993-07-15 | Sandoz Ag | Behandlung von gastrointestinalkrankheiten durch anwendung von 5-ht3-antagonisten. |
| GB8516083D0 (en) * | 1985-06-25 | 1985-07-31 | Glaxo Group Ltd | Heterocyclic compounds |
| US5578628A (en) * | 1985-06-25 | 1996-11-26 | Glaxo Group Limited | Medicaments for the treatment of nausea and vomiting |
| GB8518658D0 (en) * | 1985-07-24 | 1985-08-29 | Glaxo Group Ltd | Medicaments |
| US5204356A (en) * | 1985-07-24 | 1993-04-20 | Glaxo Group Limited | Treatment of anxiety |
| GB8525844D0 (en) * | 1985-10-19 | 1985-11-20 | Beecham Group Plc | Compounds |
| US4910193A (en) * | 1985-12-16 | 1990-03-20 | Sandoz Ltd. | Treatment of gastrointestinal disorders |
| HU202108B (en) * | 1986-07-30 | 1991-02-28 | Sandoz Ag | Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol |
| DE3777805D1 (de) * | 1986-11-21 | 1992-04-30 | Glaxo Group Ltd | Arzneimittel zur behandlung oder vorbeugung des entzugssyndromes. |
| GB8627909D0 (en) * | 1986-11-21 | 1986-12-31 | Glaxo Group Ltd | Medicaments |
| GB8628475D0 (en) * | 1986-11-28 | 1987-01-07 | Glaxo Group Ltd | Medicaments |
| EP0272052B1 (de) * | 1986-12-16 | 1992-07-08 | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) | Angstlösende N-(1-Azabicyclo[2.2.2)oct-3-yl)benzamide und -thiobenzamide |
| EP0279990B1 (de) * | 1986-12-17 | 1995-07-12 | Glaxo Group Limited | Verwendung von heterocyclischen Verbindungen zur Behandlung von Bewusstseinsstörungen |
| US5244909A (en) * | 1986-12-17 | 1993-09-14 | Glaxo Group Limited | Methods for the treatment of cognitive disorders |
| US5330982A (en) * | 1986-12-17 | 1994-07-19 | Glaxo Group Limited | Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith |
| EP0278173B1 (de) * | 1986-12-17 | 1993-11-03 | Glaxo Group Limited | Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen |
| IE60991B1 (en) * | 1986-12-17 | 1994-09-07 | Glaxo Group Ltd | Use of ketone derivatives in the treatment of cognitive disorders |
| GB8630071D0 (en) * | 1986-12-17 | 1987-01-28 | Glaxo Group Ltd | Medicaments |
| GB8806990D0 (en) * | 1988-03-23 | 1988-04-27 | Beecham Group Plc | Novel compounds |
| GB8701022D0 (en) * | 1987-01-19 | 1987-02-18 | Beecham Group Plc | Treatment |
| US4943428A (en) * | 1987-07-10 | 1990-07-24 | Wright State University | Stimulation of serotonin-1A receptors in mammals to alleviate motion sickness and emesis induced by chemical agents |
| DE3822792C2 (de) * | 1987-07-11 | 1997-11-27 | Sandoz Ag | Neue Verwendung von 5HT¶3¶-Antagonisten |
| EP0307077A1 (de) * | 1987-07-21 | 1989-03-15 | Merck Frosst Canada Inc. | Tetrahydrocarbazole zur Verbesserung der Cyclosporintherapie |
| CA1307790C (en) * | 1987-08-04 | 1992-09-22 | Ian Anthony Cliffe | Ethers |
| GB8718445D0 (en) * | 1987-08-04 | 1987-09-09 | Wyeth John & Brother Ltd | Pyridyl-ethers |
| GB8720805D0 (en) * | 1987-09-04 | 1987-10-14 | Naylor R J | 2-alkoxy-n-(1-azabicyclo(2 2 2)oct-3-yl)benzamides & thiobenzamides |
| US4863919A (en) * | 1988-02-01 | 1989-09-05 | A. H. Robins Company, Incorporated | Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes |
| EP0329932B1 (de) * | 1988-02-23 | 1995-10-18 | Merrell Pharmaceuticals Inc. | Verwendung von Chinolizin- und Chinolizinon-Derivaten zur Herstellung von Arzneimitteln |
| GB8805269D0 (en) * | 1988-03-04 | 1988-04-07 | Glaxo Group Ltd | Medicaments |
| GB8806224D0 (en) * | 1988-03-16 | 1988-04-13 | Johnson Matthey Plc | Platinum chemotherapeutic product |
| GB8816187D0 (en) * | 1988-07-07 | 1988-08-10 | Glaxo Group Ltd | Medicaments |
| IT1228288B (it) * | 1989-01-09 | 1991-06-07 | Zambon Spa | Composti ad attivita' antiserotoninica |
| AU631632B2 (en) * | 1989-04-21 | 1992-12-03 | Novartis Ag | Therapeutic use of 5-ht3 receptor antagonists |
| AU5650890A (en) * | 1989-05-24 | 1990-12-18 | Nippon Shinyaku Co. Ltd. | Indole derivatives and medicine |
| US5223613A (en) * | 1990-04-27 | 1993-06-29 | G. D. Searle & Co. | Azatetracycle compounds and process of preparing same |
| US5140023A (en) * | 1990-04-27 | 1992-08-18 | G. D. Searle & Co. | Azatetracycle compounds |
| AU8405891A (en) * | 1990-08-31 | 1992-03-30 | Nippon Shinyaku Co. Ltd. | Indole derivative and medicine |
| US5516782A (en) * | 1991-03-07 | 1996-05-14 | G. D. Searle & Co. | New meso-azacyclic aromatic acid amides and esters as novel serotonergic agents |
| US5234921A (en) * | 1991-03-07 | 1993-08-10 | G. D. Searle & Co. | Meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof as pharmaceuticals |
| AU1578692A (en) * | 1991-03-07 | 1992-10-06 | G.D. Searle & Co. | New meso-azacyclic aromatic acid amides and esters as novel serotonergic agents |
| US5137893A (en) * | 1991-03-07 | 1992-08-11 | G. D. Searle & Co. | Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof |
| US5260303A (en) * | 1991-03-07 | 1993-11-09 | G. D. Searle & Co. | Imidazopyridines as serotonergic 5-HT3 antagonists |
| US5219850A (en) * | 1991-03-07 | 1993-06-15 | G. D. Searle & Co. | Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof |
| US5227377A (en) * | 1991-03-07 | 1993-07-13 | G. D. Searle & Co. | Meso-azacyclic amides of certain bicyclic carboxylic acids |
| US5196547A (en) * | 1991-03-07 | 1993-03-23 | G. D. Searle & Co. | Meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof |
| JPH06508836A (ja) * | 1991-06-26 | 1994-10-06 | セプラコア，インコーポレーテッド | 光学的に純粋なｒ（＋）オンダンセトロンを使用する嘔吐、吐き気および他の障害の治療のための方法および組成物 |
| DE4126999A1 (de) * | 1991-08-16 | 1993-02-18 | Basf Ag | Herbizide mittel, enthaltend 3-aminobenzo(b)thiophene als antidots |
| JP2699794B2 (ja) * | 1992-03-12 | 1998-01-19 | 三菱化学株式会社 | チエノ〔３，２−ｂ〕ピリジン誘導体 |
| DE4238553A1 (de) * | 1992-11-14 | 1994-05-19 | Kali Chemie Pharma Gmbh | Neue Imidazol-1-yl-Verbindungen enthaltende Arzneimittel |
| CN1039623C (zh) * | 1993-10-22 | 1998-09-02 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种防治运动病综合征的药物组合物及其制备方法 |
| GB2325409B (en) * | 1994-06-28 | 1999-02-10 | Kenneth Francis Prendergast | Pharmaceutical use of ondansetron/cyclodextrin complexes |
| JP2002538102A (ja) | 1999-03-01 | 2002-11-12 | セプラコア インコーポレーテッド | 光学的に純粋なｒ（＋）オンダンセトロンを使用する無呼吸および無呼吸障害の治療方法 |
| US6492385B2 (en) | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| AU2001282874A1 (en) | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
| WO2002016357A2 (en) | 2000-08-18 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
| WO2002015662A2 (en) | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists |
| WO2002017358A2 (en) | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists) |
| EP1339707A2 (de) * | 2000-10-30 | 2003-09-03 | Teva Pharmaceutical Industries Ltd. | Neue kristall- und solvatformen von ondansetronhydrochlorid und verfahren zu deren herstellung |
| US20020115707A1 (en) * | 2001-01-11 | 2002-08-22 | Rami Lidor-Hadas | Process for preparing pure ondansetron hydrochloride dihydrate |
| PE20021019A1 (es) | 2001-04-19 | 2002-11-13 | Upjohn Co | Grupos azabiciclicos sustituidos |
| KR100434390B1 (ko) * | 2001-04-20 | 2004-06-04 | 안국약품 주식회사 | 1,2,3,9-테트라히드로-9-메틸-3-[(2-메틸-1ｈ-이미다졸-1-일)메틸]-4ｈ-카바졸-4-온을 유효성분으로 하는 비강분무용조성물 |
| AR036041A1 (es) * | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen |
| AR036040A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
| MXPA04000779A (es) * | 2001-08-24 | 2004-04-20 | Pharmacia & Up John Company | 7-aza[2.2.1]bicicloheptanos sustituidos con arilo para el tratamiento de enfermedades. |
| JP2005527472A (ja) * | 2001-09-12 | 2005-09-15 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 疾患治療のための置換された７−アザ［２．２．１］ビシクロヘプタン |
| DK1432707T3 (da) | 2001-10-02 | 2012-06-11 | Pharmacia & Upjohn Co Llc | Azabicyklisk-substituerede kondenserede heteroarylforbindelser til behandling af sygdomme |
| US6849620B2 (en) | 2001-10-26 | 2005-02-01 | Pfizer Inc | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| MXPA04007936A (es) | 2002-02-15 | 2004-11-26 | Upjohn Co | Compuestos de aril-sustituidos para el tratamiento de enfermedades. |
| US6894042B2 (en) * | 2002-02-19 | 2005-05-17 | Pharmacia & Upjohn Company | Azabicyclic compounds for the treatment of disease |
| CA2476681A1 (en) * | 2002-02-19 | 2003-08-28 | Bruce N. Rogers | Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease |
| MXPA04007083A (es) * | 2002-02-20 | 2004-10-29 | Upjohn Co | Compuestos azabiciclicos para el tratamiento de enfermedades. |
| US7098345B2 (en) * | 2002-04-29 | 2006-08-29 | TEVA Gyógyszergyár Zárkörüen Müködö Részvénytársaság | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one |
| US20050131045A1 (en) * | 2002-04-30 | 2005-06-16 | Judith Aronhime | Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them |
| GB0211230D0 (en) | 2002-05-16 | 2002-06-26 | Medinnova Sf | Treatment of heart failure |
| EP1542999A1 (de) | 2002-08-01 | 2005-06-22 | Pharmacia & Upjohn Company LLC | 1h-pyrazol- und 1h-pyrrol-azabicyclische verbindungen mit alpha-7-nachr-aktivität |
| JP2006506395A (ja) * | 2002-11-01 | 2006-02-23 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | ＣＮＳ疾患の治療のための、α７ニコチンアゴニスト活性及び５ＨＴ３アンタゴニスト活性を有する化合物 |
| EP1567163B1 (de) * | 2003-01-13 | 2007-04-11 | Dynogen Pharmaceuticals Inc. | Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus |
| US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
| CN100390172C (zh) * | 2004-09-10 | 2008-05-28 | 成都欣捷高新技术开发有限公司 | 一种甲磺酸多拉司琼晶型及其制备方法 |
| WO2006105117A2 (en) * | 2005-03-28 | 2006-10-05 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
| US20090227623A1 (en) * | 2007-09-15 | 2009-09-10 | Protia, Llc | Deuterium-enriched palosetron |
| MY159826A (en) | 2008-11-19 | 2017-02-15 | Forum Pharmaceuticals Inc | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
| JP5808319B2 (ja) * | 2009-05-11 | 2015-11-10 | フォルム ファーマシューティカルズ、インコーポレイテッド | アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα７ニコチン酸受容体を用いた認知障害の治療 |
| US20100298397A1 (en) * | 2009-05-19 | 2010-11-25 | Singh Nikhilesh N | Method of treatment of obsessive compulsive disorder with ondansetron |
| AR081402A1 (es) | 2010-05-17 | 2012-08-29 | Envivo Pharmaceuticals Inc | Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida monohidrato |
| AU2013259871A1 (en) | 2012-05-08 | 2014-11-20 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
| CN102887893B (zh) * | 2012-10-24 | 2015-01-14 | 齐鲁制药有限公司 | 一种托烷司琼的制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB229444A (en) * | 1924-01-03 | 1925-02-26 | Frank Samuel Pett | Improvements in ships' davits |
| DE2548968A1 (de) * | 1975-11-03 | 1977-05-12 | Thomae Gmbh Dr K | Neue amino-benzoesaeureamide |
| IL59004A0 (en) * | 1978-12-30 | 1980-03-31 | Beecham Group Ltd | Substituted benzamides their preparation and pharmaceutical compositions containing them |
| FR2493848B2 (fr) * | 1980-11-07 | 1986-05-16 | Delalande Sa | Nouveaux derives des nor-tropane et granatane, leur procede de preparation et leur application en therapeutique |
| GB2100259B (en) * | 1981-06-13 | 1984-10-31 | Merrell Toraude & Co | Treatment of migraine with tropyl benzoate derivatives |
| EP0067615B1 (de) * | 1981-06-17 | 1986-01-08 | Beecham Group Plc | Alkylthioderivate von Azabicyclobenzamiden, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen |
| AU1508183A (en) * | 1982-06-04 | 1983-12-08 | Beecham Group Plc | Benzamide and anilide derivatives of 8-azabicyclo-(3.2.1)- -octane |
| FR2531083B1 (fr) * | 1982-06-29 | 1986-11-28 | Sandoz Sa | Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments |
| EP0099194A3 (de) * | 1982-07-03 | 1984-04-11 | Beecham Group Plc | Benzamide |
| JPS5967284A (ja) * | 1982-07-13 | 1984-04-16 | サンド・アクチエンゲルシヤフト | インドリルカルボン酸ピペリジルエステル誘導体 |
| EP0102195A3 (de) * | 1982-08-03 | 1984-04-11 | Beecham Group Plc | Substituierte Azabicycloalkyl-Derivate mit dopaminantagonistischer Wirkung |
| JPS5944383A (ja) * | 1982-08-03 | 1984-03-12 | ビ−チヤム・グル−プ・ピ−エルシ− | 新規な化合物、その製法及びその用途 |
| EP0135545A1 (de) * | 1983-02-19 | 1985-04-03 | Beecham Group Plc | Azabicycloalkyl-derivate von benzamid und anilid |
| FR2557110B1 (fr) * | 1983-12-23 | 1989-11-24 | Sandoz Sa | Nouveaux derives d'amines cycliques, leur preparation et leur utilisation comme medicaments |
| NL190373C (nl) * | 1984-01-25 | 1994-02-01 | Glaxo Group Ltd | Een 3-gesubstitueerde aminomethyl-2,3-dihydro-4(1h)-carbazolon, werkwijze ter bereiding daarvan, alsmede een farmaceutisch preparaat. |
| US4593034A (en) * | 1984-04-06 | 1986-06-03 | A. H. Robins Company, Inc. | 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides |
| EP0158265A2 (de) * | 1984-04-13 | 1985-10-16 | Beecham Group Plc | Benzamid- und Anilid-Derivate |
| DE3587151T2 (de) * | 1984-12-20 | 1993-07-15 | Sandoz Ag | Behandlung von gastrointestinalkrankheiten durch anwendung von 5-ht3-antagonisten. |
| DE3680123D1 (en) * | 1985-01-23 | 1991-08-14 | Glaxo Group Ltd | Tetrahydrocarbazolonderivate. |
| GB8516083D0 (en) * | 1985-06-25 | 1985-07-31 | Glaxo Group Ltd | Heterocyclic compounds |
| GB8518658D0 (en) * | 1985-07-24 | 1985-08-29 | Glaxo Group Ltd | Medicaments |
| HU202108B (en) * | 1986-07-30 | 1991-02-28 | Sandoz Ag | Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol |
| EP0272052B1 (de) * | 1986-12-16 | 1992-07-08 | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) | Angstlösende N-(1-Azabicyclo[2.2.2)oct-3-yl)benzamide und -thiobenzamide |
| GB8806224D0 (en) * | 1988-03-16 | 1988-04-13 | Johnson Matthey Plc | Platinum chemotherapeutic product |
-
1986
- 1986-03-10 DE DE3689974T patent/DE3689974T2/de not_active Expired - Lifetime
- 1986-03-10 DE DE199090107640T patent/DE385517T1/de active Pending
- 1986-03-10 DE DE198686301684T patent/DE201165T1/de active Pending
- 1986-03-10 EP EP19900115499 patent/EP0405617A3/en not_active Withdrawn
- 1986-03-10 EP EP86301684A patent/EP0201165B1/de not_active Expired - Lifetime
- 1986-03-10 EP EP90107640A patent/EP0385517B1/de not_active Expired - Lifetime
- 1986-03-10 DE DE90107640T patent/DE3688296T2/de not_active Expired - Lifetime
- 1986-03-12 US US06/838,904 patent/US4721720A/en not_active Expired - Lifetime
- 1986-03-13 JP JP61053809A patent/JPS61212521A/ja active Granted
-
1987
- 1987-07-09 US US07/071,424 patent/US4783478A/en not_active Expired - Lifetime
-
1988
- 1988-09-16 US US07/245,892 patent/US4851407A/en not_active Expired - Lifetime
-
1992
- 1992-06-02 JP JP4165493A patent/JPH0720863B2/ja not_active Expired - Lifetime
-
1993
- 1993-05-07 SG SG616/93A patent/SG61693G/en unknown
- 1993-07-29 HK HK775/93A patent/HK77593A/xx not_active IP Right Cessation
-
1994
- 1994-05-06 CY CY172794A patent/CY1727A/xx unknown
- 1994-06-06 JP JP6145767A patent/JPH0748372A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US4721720A (en) | 1988-01-26 |
| HK77593A (en) | 1993-08-06 |
| JPH0748372A (ja) | 1995-02-21 |
| EP0385517B1 (de) | 1993-04-14 |
| SG61693G (en) | 1993-07-09 |
| DE385517T1 (de) | 1991-07-25 |
| EP0201165B1 (de) | 1994-07-20 |
| JPH0555484B2 (de) | 1993-08-17 |
| US4721720B1 (de) | 1992-06-30 |
| EP0385517A2 (de) | 1990-09-05 |
| JPS61212521A (ja) | 1986-09-20 |
| EP0385517A3 (en) | 1990-10-31 |
| JPH0720863B2 (ja) | 1995-03-08 |
| EP0201165A3 (en) | 1990-08-16 |
| DE3688296T2 (de) | 1993-11-04 |
| EP0201165A2 (de) | 1986-11-12 |
| DE3688296D1 (de) | 1993-05-19 |
| JPH05310734A (ja) | 1993-11-22 |
| CY1727A (en) | 1994-05-06 |
| US4851407A (en) | 1989-07-25 |
| US4783478A (en) | 1988-11-08 |
| EP0405617A2 (de) | 1991-01-02 |
| DE3689974T2 (de) | 1994-11-03 |
| DE3689974D1 (de) | 1994-08-25 |
| EP0405617A3 (en) | 1992-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE201165T1 (de) | Arzneimittel zur behandlung von emesis, anxietas und "irritable bowel syndrome". | |
| ES479021A1 (es) | Procedimiento para preparar composiones insecticidas y aca- ricidas a base de derivados sustituidos de fenoxibenciloxi- carbonilo. | |
| DE137145T1 (de) | Camptothecin-derivate und verfahren zu deren herstellung. | |
| EP0237962A3 (de) | 2-Azolylmethyl-2-aryl-1,3-dioxolane und deren Salze, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung | |
| RU2002107318A (ru) | Новые фенилпиперазины | |
| KR850008342A (ko) | N-알케닐-3-히드록시벤조 [b]티오펜-2-카복스아미드 유도체의 제조방법 | |
| ATE144983T1 (de) | Neue tricyclische verbindung oder salze davon, verfahren zur herstellung und antimikrobieller wirkstoff, der sie enthält | |
| ES482700A1 (es) | Procedimiento para la obtencion de alfa-azolil-beta-hidroxi-cetonas. | |
| ATE193531T1 (de) | Phenyl-carboxamide-isoxazole-derivate und salze, verfahren zu ihrer herstellung ihre anwendung als arzneimittel und pharmazeutische zusammensetzungen die sie enthalten | |
| EP0086416A3 (de) | Corynanthein-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel | |
| ATE24503T1 (de) | Phenylpiperazin-derivate und verfahren zu deren herstellung. | |
| GB2020279A (en) | Piperazinylbenzoheterocyclic compounds | |
| EP0207004A3 (de) | Substituierte 4,5-Dihydro-1,3,4-thiadiazole | |
| EP0401168A3 (de) | Neue Herbizide | |
| ATE185145T1 (de) | 11 beta-benzaldoxim-9 alpha, 10 alpha-epoxy-estr- 4-en-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische präparate | |
| EP0123998A3 (de) | 4-Phenyl-tetrahydro-furano-pyridine, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen | |
| EP0029966A3 (de) | Cephalosporinderivate, und deren Herstellung sowie entsprechende pharmazeutische Präparate | |
| EP0153582A3 (de) | 1,3,2-Dioxaborinane | |
| RO78871B (ro) | Procedeu pentru prepararea unor derivati de piridiluree si piridiltiouree | |
| ATE10844T1 (de) | Chinolincarbonsaeurederivat, verfahren zu seiner herstellung und es enthaltende bakterizide mittel. | |
| ATE3035T1 (de) | Azolyl-alkenole, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide. | |
| DE2140280A1 (de) | 4 Amino 2 eckige Klammer auf 2 (5 Nitro 2 furyl)vinyl eckige Klammer zu chinazolinderivate, Herstellungsver fahren dafür und Arzneimittel daraus | |
| AT366660B (de) | Verfahren zur herstellung neuer allylamine | |
| EP0143302A3 (de) | Neue Benzoylharnstoff-Derivate und Zwischenprodukte | |
| DE2752253C3 (de) |